<DOC>
	<DOCNO>NCT00072436</DOCNO>
	<brief_summary>This phase I trial study side effect best dose gemcitabine hydrochloride alvocidib treat patient solid tumor . Drugs use chemotherapy , gemcitabine hydrochloride alvocidib , use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell</brief_summary>
	<brief_title>Gemcitabine Hydrochloride Alvocidib Treating Patients With Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose gemcitabine flavopiridol patient solid tumor . SECONDARY OBJECTIVES : I . Determine safety profile toxic effect regimen patient . II . Determine pharmacokinetics flavopiridol without gemcitabine patient . III . Determine , use pharmacodynamic assay , activity flavopiridol cdk inhibitor patient . IV . Determine , use pharmacodynamic assay , marker regimen patient . OUTLINE : This dose-escalation , multicenter study . Some patient receive initial dose alvocidib IV 1-7 hour day 1 ( course 0 ) . Beginning 1 week later subsequent course , patient receive gemcitabine hydrochloride IV 60-150 minute day 1 15 alvocidib IV 1-7 hour day 2 16 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos gemcitabine hydrochloride alvocidib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , 10 additional patient receive treatment dose . Patients follow 30 day study completion .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<criteria>Negative pregnancy test Fertile patient must use effective contraception No active infection No severe malnutrition No 2 prior chemotherapy regimen : Prior combine modality therapy ( e.g. , fulldose chemotherapy radiosensitizing chemotherapy radiotherapy ) consider 1 prior regimen therapy deliver part 1 comprehensive treatment plan More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No concurrent chemotherapy At least 6 month since prior radiotherapy lung parenchyma mediastinum evidence radiation pneumonitis chest CT scan At least 4 week since prior radiotherapy recover No prior radiotherapy 50 % marrow volume No concurrent radiotherapy Histologically confirm solid tumor gemcitabine treatment option OR efficacious therapy exist Must meet criterion 1 follow : Measurable disease : At least 1 unidimensionally measurable lesion least 20 mm conventional technique OR least 10 mm spiral CT scan Nonmeasurable disease , include follow : Small lesion ( less 20 mm conventional technique OR le 10 mm spiral CT scan ) Bone lesion Cytologically positive pleural peritoneal disease Elevated tumor marker ( e.g. , carcinoembryonic antigen , CA 125 , CA 199 , tumor marker ) Multinodular confluent nonmeasurable pulmonary , hepatic , adrenal , intraabdominal , skin metastases No active CNS metastases Previously treat CNS metastasis must stable symptom 4 week completion treatment AND patient must steroid therapy stable dose least past 2 week No know leptomeningeal metastasis Performance status : ECOG 01 Hematopoietic : Absolute neutrophil count least 1,500/mm3 ; Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL ; SGOT great 2.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular : None follow within past 6 month : Myocardial infarction ; Unstable angina ; Transient ischemic attack ; Cerebrovascular accident No new cardiac arrhythmia possibly related cardiac ischemia ; No large potentially symptomatic pericardial effusion ; No cardiac disease would preclude study participation Pulmonary : No pulmonary embolism within past 6 month ; No large potentially symptomatic pleural effusion ; No pulmonary disease would preclude study participation Gastrointestinal : No intractable emesis ; No grade 2 great chronic diarrheal disease within past 6 month Not pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>